Hydergin en es it fr

Hydergin Brand names, Hydergin Analogs

Hydergin Brand Names Mixture

  • No information avaliable

Hydergin Chemical_Formula


Hydergin RX_link

No information avaliable

Hydergin fda sheet

Hydergin msds (material safety sheet)

Hydergin Synthesis Reference

No information avaliable

Hydergin Molecular Weight

591.741 g/mol

Hydergin Melting Point

No information avaliable

Hydergin H2O Solubility

No information avaliable

Hydergin State


Hydergin LogP


Hydergin Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Hydergin Indication

For use as an adjunct therapy for patients with dementia

Hydergin Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Hydergin Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Hydergin side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Hydergin Patient Information

No information avaliable

Hydergin Organisms Affected

Humans and other mammals